SERUM NEURON-SPECIFIC ENOLASE IN PATIENTS DURING THE ACUTE PERIOD OF ISCHEMIC STROKE WITH CONCOMITANT OBSTRUCTIVE SLEEP APNEA SYNDROME

Authors

  • O. Yu. Bilas Ivano-Frankivsk National Medical University
  • I. I. Titov Ivano-Frankivsk National Medical University

DOI:

https://doi.org/10.11603/1811-2471.2024.v.i1.14458

Keywords:

Neuron-specific enolase, ischemic stroke, obstructive sleep apnea syndrome, CPAP-therapy, respiratory support

Abstract

SUMMARY. The work is devoted to the study of the dynamics of changes in the marker of ischemia of neurons – neuron-specific enolase (NSE), in patients during the acute period of ischemic stroke and the concomitant obstructive sleep apnea syndrome (OSAS).

The aim – to study the dynamics of NSE changes in patients during the acute period of ischemic stroke with concomitant OSAS against the background of non-invasive respiratory support.

Material and Methods. There were observed 60 patients with a verified ischemic stroke (1–13 points according to NIHSS), who were performed somnological examinations during the first day of the stroke and OSAS was detected, which required respiratory correction. Patients were divided into two groups. Group I patients, who for various reasons refused to use respiratory support, continued to be treated according to the clinical protocol. For the patients of group II, the basic treatment was supplemented with the respiratory support. The level of NSE was determined by the immunoenzymatic method during the first day of hospitalization and after 7 and 14 days of treatment. Statistical analysis was performed using the licensed program STATISTICA 12 (StatSoft Inc., USA). The significance level of differences was p<0.05.

Results. The initial values of the median NSE level in patients of the groups I and II were 31.17 [28.54–38.41] ng/ml and 32.65 [28.71–43.65] ng/ml, respectively. After 7 days of treatment, the NSE level decreased at 15.2 % in patients of the group I, and at 22.7 % (p<0.001) during the 14th day to the level of 24.09 [22.36–28.48] ng/ml, compared to the initial values. In patients of the group II, the level of NSE decreased at 40.4 % (p<0.001) already during the 7th day of therapy, and during the 14th day at 56.3 % (p<0.001) to the level of 14.28 [12.49–16.22] ng/ml, compared with the original values.

Conclusions. Serum NSE – is a highly sensitive index of the severity of ischemic brain damage, which can be used to evaluate the effectiveness of various treatment strategies in patients with the ischemic stroke. Supplementation of the basic complex with non-invasive respiratory support (auto CPAP-therapy) ensured a decrease in the level of serum NSE at 40.4 % during the 7th day and at 56.3 % (p<0.001) during the 14th day of observation to the limit of 14.28 ng/ml.

References

Feigin, V.L., Brainin, M., Norrving, B., Martins, S., Sacco, R.L., Hacke, W., Fisher, M., Pandian, J., & Lindsay, P. (2022). World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. International journal of stroke : official journal of the International Stroke Society, 17(1), 18-29. DOI: 10.1177/17474930211065917.

Birkbak, J., Clark, A.J., & Rod, N.H. (2014). The effect of sleep disordered breathing on the outcome of stroke and transient ischemic attack: a systematic review. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 10(1), 103-108. DOI: 10.5664/jcsm.3376.

Kim, Y., Koo, Y.S., Lee, H.Y., & Lee, S.Y. (2016). Can Continuous Positive Airway Pressure Reduce the Risk of Stroke in Obstructive Sleep Apnea Patients? A Systematic Review and Meta-Analysis. PloS One, 11(1), e0146317. DOI: 10.1371/journal.pone.0146317.

Anand, N., & Stead, L.G. (2005). Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovascular diseases (Basel, Switzerland), 20(4), 213-219. DOI: 10.1159/000087701.

Mochetti, M.M., Silva, E.G.P., Correa, A.A.F., Cabette, M.R., Perissinotti, I.N., E Silva, L.O.J., Pessoa, A.S., … de Alencar, J.C.G. (2024). Neuron-specific enolase at admission as a predictor for stroke volume, severity and outcome in ischemic stroke patients: a prognostic biomarker review. Scientific reports, 14(1), 2688. DOI: 10.1038/s41598-024-53080-6.

(2008). Helsinska deklaratsiia Vsesvitnoi medychnoi asotsiatsii "Etychni pryntsypy medychnykh doslidzhen za uchastiu liudyny u yakosti obiekta doslidzhennia" No 990_005 vid 01.10.2008 [Helsinki Declaration of the World Medical Association "Ethical Principles of Medical Research with the participation of a person as an object of study" Document No. 990_005 of 01.10.2008]. Retrieved from: https://zakon.rada.gov.ua/laws/show/990_005#Text [in Ukrainian].

Stanton, A.G. (2012). Primer of Biostatistics. 7th ed. New York : The McGraw-Hill Publishing Co., 459.

Stadnik, S.M., Saiko, O.V., & Dumchenko, O.I. (2020). Neironspetsyfichna enolaza yak marker poshkodzhennia mozkovoi tkanyny u patsiientiv z ishemichnym insultom [Neuronspecific enolaza as a marker of cerebral tissue in patients with ischemic stroke]. Nevidkladna medytsyna – Emergency medicine, 16(6), 66-71. DOI: 10.22141/2224-0586.16.6. 2020.216512 [in Ukrainian].

Halushko, O.A. (2017). Syndrom obstruktyvnoho apnoe snu u khvorykh na hostryi insult: diahnostyka i taktyka respiratornoi pidtrymky [Obstructive sleep apnea syndrome in acute stroke patients: diagnosis and tactics of respiratory support]. Bil, znebolennia ta intensyvna terapiia – Pain, analgesia and intensive care, 4(81), 54-60. DOI: 10. 25284/2519-2078.4(81).2017.119307 [in Ukrainian].

Published

2024-03-28

How to Cite

Bilas, O. Y., & Titov, I. I. (2024). SERUM NEURON-SPECIFIC ENOLASE IN PATIENTS DURING THE ACUTE PERIOD OF ISCHEMIC STROKE WITH CONCOMITANT OBSTRUCTIVE SLEEP APNEA SYNDROME. Achievements of Clinical and Experimental Medicine, (1), 45–50. https://doi.org/10.11603/1811-2471.2024.v.i1.14458

Issue

Section

Оригінальні дослідження